PBM Capital Group Invests in Xalud Therapeutics Gene Therapy Platform for Treatment of Neuro-Inflammatory Diseases

Business News
Print
CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--PBM Capital Group, a healthcare-focused private investment firm, announces an investment in Xalud Therapeutics (www.xaludthera.com). This round of financing will help support the company’s gene therapy platform targeting multiple neuro-inflammatory diseases. PBM will have two representatives on Xalud’s Board of Directors and will also provide operational support to the Company. Xalud Therapeutics is an IND-stage platform gene therapy company developing nov

imageimage